ACADIA PHARMACEUTICALS INC. Operating Expenses
ACADIA PHARMACEUTICALS INC. (ACAD) reported Operating Expenses of $50.27 million for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2016-05-05
- ACADIA PHARMACEUTICALS INC. operating expenses for the quarter ending 2016-03-31 was $50.27M, a 23.94% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating expenses for the quarter ending 2015-12-31 was $45.58M, a 59.37% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating expenses for the quarter ending 2015-09-30 was $39.04M, a 56.09% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating expenses for the quarter ending 2015-06-30 was $39.50M, a 81.59% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating expenses for fiscal 2015 was $164.67M, a 76.40% increase from fiscal 2014.
- ACADIA PHARMACEUTICALS INC. operating expenses for fiscal 2014 was $93.35M, a 136.68% increase from fiscal 2013.
- ACADIA PHARMACEUTICALS INC. operating expenses for fiscal 2013 was $39.44M, a 52.92% increase from fiscal 2012.
- ACADIA PHARMACEUTICALS INC. operating expenses for fiscal 2012 was $25.79M, a 3.51% increase from fiscal 2011.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2016-03-31 | $50.27M 10-Q · filed 2016-05-05 | $95.85M derived: sum of 2 quarters · filed 2016-05-05 | $134.88M derived: sum of 3 quarters · filed 2016-05-05 | $174.38M derived: sum of 4 quarters · filed 2016-05-05 |
| 2015-12-31 | $45.58M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $84.62M derived: sum of 2 quarters · filed 2016-02-29 | $124.12M derived: sum of 3 quarters · filed 2016-02-29 | $164.67M 10-K · filed 2016-02-29 |
| 2015-09-30 | $39.04M 10-Q · filed 2015-11-05 | $78.53M derived: sum of 2 quarters · filed 2015-11-05 | $119.09M 10-Q · filed 2015-11-05 | $147.69M derived: sum of 4 quarters · filed 2016-05-05 |
| 2015-06-30 | $39.50M 10-Q · filed 2015-08-06 | $80.05M 10-Q · filed 2015-08-06 | $108.66M derived: sum of 3 quarters · filed 2016-05-05 | $133.66M derived: sum of 4 quarters · filed 2016-05-05 |
| 2015-03-31 | $40.56M 10-Q · filed 2016-05-05 | $69.16M derived: sum of 2 quarters · filed 2016-05-05 | $94.17M derived: sum of 3 quarters · filed 2016-05-05 | $115.92M derived: sum of 4 quarters · filed 2016-05-05 |
| 2014-12-31 | $28.60M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $53.61M derived: sum of 2 quarters · filed 2016-02-29 | $75.36M derived: sum of 3 quarters · filed 2016-02-29 | $93.35M 10-K · filed 2016-02-29 |
| 2014-09-30 | $25.01M 10-Q · filed 2015-11-05 | $46.76M derived: sum of 2 quarters · filed 2015-11-05 | $64.75M 10-Q · filed 2015-11-05 | $76.95M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $21.75M 10-Q · filed 2015-08-06 | $39.74M 10-Q · filed 2015-08-06 | $51.94M derived: sum of 3 quarters · filed 2016-02-29 | $62.99M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $17.99M 10-Q · filed 2015-05-07 | $30.19M derived: sum of 2 quarters · filed 2016-02-29 | $41.24M derived: sum of 3 quarters · filed 2016-02-29 | $50.85M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $12.20M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $23.25M derived: sum of 2 quarters · filed 2016-02-29 | $32.86M derived: sum of 3 quarters · filed 2016-02-29 | $39.44M 10-K · filed 2016-02-29 |
| 2013-09-30 | $11.05M 10-Q · filed 2014-11-10 | $20.66M derived: sum of 2 quarters · filed 2014-11-10 | $27.24M 10-Q · filed 2014-11-10 | $34.44M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $9.61M 10-Q · filed 2014-08-05 | $16.19M 10-Q · filed 2014-08-05 | $23.39M derived: sum of 3 quarters · filed 2015-02-26 | $29.27M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $6.58M 10-Q · filed 2014-05-06 | $13.78M derived: sum of 2 quarters · filed 2015-02-26 | $19.66M derived: sum of 3 quarters · filed 2015-02-26 | $25.69M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $13.08M derived: sum of 2 quarters · filed 2015-02-26 | $19.11M derived: sum of 3 quarters · filed 2015-02-26 | $25.79M 10-K · filed 2015-02-26 |
| 2012-09-30 | $5.88M 10-Q · filed 2013-11-06 | $11.91M derived: sum of 2 quarters · filed 2013-11-06 | $18.59M 10-Q · filed 2013-11-06 | $24.50M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $6.03M 10-Q · filed 2013-08-06 | $12.71M 10-Q · filed 2013-08-06 | $18.61M derived: sum of 3 quarters · filed 2014-02-27 | $24.29M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $6.68M 10-Q · filed 2013-05-07 | $12.58M derived: sum of 2 quarters · filed 2014-02-27 | $18.26M derived: sum of 3 quarters · filed 2014-02-27 | $25.30M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $5.90M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $11.58M derived: sum of 2 quarters · filed 2014-02-27 | $18.62M derived: sum of 3 quarters · filed 2014-02-27 | $24.92M 10-K · filed 2014-02-27 |
| 2011-09-30 | $5.68M 10-Q · filed 2012-11-05 | $12.72M derived: sum of 2 quarters · filed 2012-11-05 | $19.02M 10-Q · filed 2012-11-05 | $25.29M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-06-30 | $7.04M 10-Q · filed 2012-08-08 | $13.34M 10-Q · filed 2012-08-08 | $19.61M derived: sum of 3 quarters · filed 2013-03-12 | $26.16M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-03-31 | $6.30M 10-Q · filed 2012-05-08 | $12.57M derived: sum of 2 quarters · filed 2013-03-12 | $19.11M derived: sum of 3 quarters · filed 2013-03-12 | $25.71M derived: sum of 4 quarters · filed 2013-03-12 |
| 2010-12-31 | $6.28M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $12.82M derived: sum of 2 quarters · filed 2013-03-12 | $19.41M derived: sum of 3 quarters · filed 2013-03-12 | $27.04M 10-K · filed 2013-03-12 |
| 2010-09-30 | $6.54M 10-Q · filed 2011-11-09 | $13.14M derived: sum of 2 quarters · filed 2011-11-09 | $20.77M 10-Q · filed 2011-11-09 | |
| 2010-06-30 | $6.59M 10-Q · filed 2011-08-10 | $14.22M 10-Q · filed 2011-08-10 | ||
| 2009-12-31 | $51.87M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |